Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018

Details for Mechanism ID: 18108
Country/Region: Mozambique
Year: 2018
Main Partner: Johns Hopkins University
Main Partner Program: JHPIEGO
Organizational Type: University
Funding Agency: USDOD
Total Funding: $3,883,509 Additional Pipeline Funding: $237,846

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $675,011
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $187,503
Care: Pediatric Care and Support (PDCS) $37,501
Laboratory Infrastructure (HLAB) $80,350
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $39,575
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Prevention: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $13,523
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $2,812,545
Treatment: Pediatric Treatment (PDTX) $37,501
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive 2019 105
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive 2019 75
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive 2019 70
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive 2019 61
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 3,132
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Positive 2019 55
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Positive 2019 105
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 1
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2019 257
PMTCT_ART_DSD New on ART 2019 214
PMTCT_ART_DSD Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 471
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 3,132
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2019 302
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2019 75
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 377
PMTCT_EID_DSD Sum of Infant Age disaggregates 2019 377
PMTCT_STAT_DSD By Age (Denominator): 10-14 2019 6
PMTCT_STAT_DSD By Age (Denominator): 20-24 2019 987
PMTCT_STAT_DSD By Age (Denominator): <15-19 2019 747
PMTCT_STAT_DSD By Age (Numerator): 10-14 2019 6
PMTCT_STAT_DSD By Age (Numerator): 15-19 2019 747
PMTCT_STAT_DSD By Age (Numerator): 20-24 2019 987
PMTCT_STAT_DSD By Number of known positives: 15-19 2019 55
PMTCT_STAT_DSD By Number of known positives: 20-24 2019 105
PMTCT_STAT_DSD By Number of new negative: 10-14 2019 8
PMTCT_STAT_DSD By Number of new negative: 15-19 2019 180
PMTCT_STAT_DSD By Number of new negative: 20-24 2019 510
PMTCT_STAT_DSD By Number of new positives: 15-19 2019 22
PMTCT_STAT_DSD By Number of new positives: 20-24 2019 57
PMTCT_STAT_DSD Number of new ANC and L&D clients 2019 3,132
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 3,132
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 25-29, Female 2019 1,199
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 30-34, Female 2019 71
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 35-39, Female 2019 64
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 40-49, Female 2019 58
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 25-29, Female 2019 1,199
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 30-34, Female 2019 71
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 35-39, Female 2019 64
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 40-49, Female 2019 58
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive 2019 105
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative 2019 435
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive 2019 48
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive 2019 75
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative 2019 435
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive 2019 48
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive 2019 70
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative 2019 425
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive 2019 48
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive 2019 61
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative 2019 399
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive 2019 46
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 182
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 5
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 260
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 9
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 455
TB_PREV_DSD By Age/Sex (Denominator): 15+, Female 2019 9,695
TB_PREV_DSD By Age/Sex (Denominator): 15+, Male 2019 5,597
TB_PREV_DSD By Age/Sex (Denominator): <15, Female 2019 415
TB_PREV_DSD By Age/Sex (Denominator): <15, Male 2019 377
TB_PREV_DSD By Age/Sex (Numerator): 15+, Female 2019 3,949
TB_PREV_DSD By Age/Sex (Numerator): 15+, Male 2019 2,179
TB_PREV_DSD By Age/Sex (Numerator): <15, Female 2019 162
TB_PREV_DSD By Age/Sex (Numerator): <15, Male 2019 144
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 3,217
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 12,868
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 1,287
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 5,147
TB_PREV_DSD The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 6,434
TB_PREV_DSD The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 16,085
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 370
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 370
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 404
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 404
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 6
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 6
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 780
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2019 780
TX_CURR_DSD Age/Sex: 10-14 Female 2019 79
TX_CURR_DSD Age/Sex: 10-14 Male 2019 78
TX_CURR_DSD Age/Sex: 15-19 Female 2019 269
TX_CURR_DSD Age/Sex: 15-19 Male 2019 142
TX_CURR_DSD Age/Sex: 20-24 Female 2019 571
TX_CURR_DSD Age/Sex: 20-24 Male 2019 176
TX_CURR_DSD Age/Sex: 50+ Female 2019 1,866
TX_CURR_DSD Age/Sex: 50+ Male 2019 2,371
TX_CURR_DSD Age/Sex: <1 2019 6
TX_CURR_DSD Age/Sex: <1-9 2019 183
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2019 17,295
TX_CURR_DSD Sum of age/sex disaggregates 2019 411
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 1,873
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 1,015
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 1,873
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 1,015
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 1,873
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 1,015
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 1,873
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 1,015
TX_NEW_DSD Breastfeeding status 2019 161
TX_NEW_DSD By Age/Sex: 1-9 2019 43
TX_NEW_DSD By Age/Sex: 10-14 Female 2019 10
TX_NEW_DSD By Age/Sex: 10-14 Male 2019 10
TX_NEW_DSD By Age/Sex: 15-19 Female 2019 263
TX_NEW_DSD By Age/Sex: 15-19 Male 2019 39
TX_NEW_DSD By Age/Sex: 20-24 Female 2019 409
TX_NEW_DSD By Age/Sex: 20-24 Male 2019 177
TX_NEW_DSD By Age/Sex: 50+ Female 2019 308
TX_NEW_DSD By Age/Sex: 50+ Male 2019 545
TX_NEW_DSD By Age/Sex: <1 2019 34
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 5,635
TX_NEW_DSD Pregnancy status 2019 214
TX_NEW_DSD Sum of Age/Sex disaggregates 2019 1,761
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 497
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 452
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 497
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 452
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 497
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 452
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 497
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 452
TX_PVLS_DSD 15+, Undocumented Test Indication, Female 2019 6,822
TX_PVLS_DSD 15+, Undocumented Test Indication, Male 2019 4,522
TX_PVLS_DSD <15, Undocumented Test Indication, Female 2019 232
TX_PVLS_DSD <15, Undocumented Test Indication, Male 2019 160
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 11,736
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,748
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,487
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,594
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,421
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 56
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 51
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 34
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 30
TX_RET_DSD Denominator by Status: Breastfeeding 2019 127
TX_RET_DSD Denominator by Status: Pregnant 2019 369
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 3,989
TX_RET_DSD Numerator by Status: Breastfeeding 2019 79
TX_RET_DSD Numerator by Status: Pregnant 2019 221
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 4,432
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Female 2019 336
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Male 2019 210
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Female 2019 10,392
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Male 2019 6,355
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 79
TX_TB_DSD Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 79
TX_TB_DSD Number of ART patients who were screened for TB at least once during the reporting period 2019 17,295
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive 2019 11,761
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive 2019 1,384
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive 2019 3,805
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive 2019 345
Cross Cutting Budget Categories and Known Amounts Total: $100,000
Condoms: Policy, Tools, and Services $100,000